No Data
Top Gap Ups and Downs on Friday: NVO, TM, INFY and More
BeiGene Shares Climb Pre-Bell After FDA Gives Favorable Opinion on Class of Cancer Treatments
Trending Industry Today: WUXI APPTEC Leads Gains In Biotechnology Stocks
BeiGene Announces Board and Committee Structure
Express News | Beigene: Odac Members Voted 11 to 1, With 1 Abstaining, That Risk Benefit Profile Was Not Favorable for Escc Patients With Pd-L1 Expression
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, Including TEVIMBRA, for Treatment of ESCC and Gastric/GEJ Cancers
No Data
No Data
